Raynovent Announces Initiation of Phase 2 Clinical Trial of ZSP1273, a Category 1 Drug Intended to Treat and Prevent Influenza A and Human Avian Influenza.

Time:2019.08.25Views:64Author:Raynovent

Previous:Dr. Chen Xiaoxin, Vice President of Raynovent was Invited to Attend Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019.

Next:Raynovent Announces Receiving of Certificate of Invention Patent